Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

British Heart Journal logoLink to British Heart Journal
. 1984 Nov;52(5):530–535. doi: 10.1136/hrt.52.5.530

Captopril in heart failure. A double blind controlled trial.

J G Cleland, H J Dargie, G P Hodsman, S G Ball, J I Robertson, J J Morton, B W East, I Robertson, G D Murray, G Gillen
PMCID: PMC481676  PMID: 6388612

Abstract

The effect of the converting enzyme inhibitor captopril as long term treatment was investigated in 14 patients with severe congestive heart failure in a double blind trial. Captopril reduced plasma concentrations of angiotensin II and noradrenaline, with a converse increase in active renin concentration. Effective renal plasma flow increased and renal vascular resistance fell; glomerular filtration rate did not change. Serum urea and creatinine concentrations rose. Both serum and total body potassium contents increased; there were no long term changes in serum concentration or total body content of sodium. Exercise tolerance was appreciably improved, and dyspnoea and fatigue lessened. Left ventricular end systolic and end diastolic dimensions were reduced. There was an appreciable reduction in complex ventricular ectopic rhythms. Adverse effects were few: weight gain and fluid retention were evident in five patients when captopril was introduced and two patients initially experienced mild postural dizziness; rashes in two patients did not recur when the drug was reintroduced at a lower dose; there was a significant reduction in white cell count overall, but the lowest individual white cell count was 4000 X 10(6)/l. Captopril thus seemed to be of considerable value in the long term treatment of severe cardiac failure.

Full text

PDF
530

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atkinson A. B., Morton J. J., Brown J. J., Davies D. L., Fraser R., Kelly P., Leckie B., Lever A. F., Robertson J. I. Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition. Br Heart J. 1980 Sep;44(3):290–296. doi: 10.1136/hrt.44.3.290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Atkinson A. B., Robertson J. I. Captopril in the treatment of clinical hypertension and cardiac failure. Lancet. 1979 Oct 20;2(8147):836–839. doi: 10.1016/s0140-6736(79)92186-x. [DOI] [PubMed] [Google Scholar]
  3. Ball S. G., Tree M., Morton J. J., Inglis G. C., Fraser R. Circulating dopamine: its effect on the plasma concentrations of catecholamines, renin, angiotensin, aldosterone and vasopressin in the conscious dog. Clin Sci (Lond) 1981 Oct;61(4):417–422. doi: 10.1042/cs0610417. [DOI] [PubMed] [Google Scholar]
  4. Boddy K., Brown J. J., Davies D. L., Elliott A., Harvey I., Haywood J. K., Holloway I., Lever A. F., Robertson J. I., Williams E. D. Concurrent estimation of total body and exchangeable body sodium in hypertension. Clin Sci Mol Med. 1978 Feb;54(2):187–191. doi: 10.1042/cs0540187. [DOI] [PubMed] [Google Scholar]
  5. Brown J. J., Davies D. L., Johnson V. W., Lever A. F., Robertson J. I. Renin relationships in congestive cardiac failure, treated and untreated. Am Heart J. 1970 Sep;80(3):329–342. doi: 10.1016/0002-8703(70)90098-0. [DOI] [PubMed] [Google Scholar]
  6. Chantler C., Garnett E. S., Parsons V., Veall N. Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA. Clin Sci. 1969 Aug;37(1):169–180. [PubMed] [Google Scholar]
  7. Cohn J. N. Progress in vasodilator therapy for heart failure. N Engl J Med. 1980 Jun 19;302(25):1414–1416. doi: 10.1056/NEJM198006193022509. [DOI] [PubMed] [Google Scholar]
  8. Cowley A. J., Rowley J. M., Stainer K. L., Hampton J. R. Captopril therapy for heart failure. A placebo controlled study. Lancet. 1982 Oct 2;2(8301):730–732. doi: 10.1016/s0140-6736(82)90920-5. [DOI] [PubMed] [Google Scholar]
  9. Ellis K. J., Vaswani A., Zanzi I., Cohn S. H. Total body sodium and chlorine in normal adults. Metabolism. 1976 Jun;25(6):645–654. doi: 10.1016/0026-0495(76)90061-5. [DOI] [PubMed] [Google Scholar]
  10. Franciosa J. A., Wilen M., Ziesche S., Cohn J. N. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 1983 Mar 1;51(5):831–836. doi: 10.1016/s0002-9149(83)80141-6. [DOI] [PubMed] [Google Scholar]
  11. Fraser R., Guest S., Young J. A comparison of double-isotope derivative and radioimmunological estimation of plasma aldosterone concentration in man. Clin Sci Mol Med. 1973 Sep;45(3):411–415. doi: 10.1042/cs0450411. [DOI] [PubMed] [Google Scholar]
  12. Kramer B. L., Massie B. M., Topic N. Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study. Circulation. 1983 Apr;67(4):807–816. doi: 10.1161/01.cir.67.4.807. [DOI] [PubMed] [Google Scholar]
  13. Levine T. B., Franciosa J. A., Cohn J. N. Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure. Circulation. 1980 Jul;62(1):35–41. doi: 10.1161/01.cir.62.1.35. [DOI] [PubMed] [Google Scholar]
  14. Nicholls M. G., Ikram H., Espiner E. A., Maslowski A. H., Scandrett M. S., Penman T. Hemodynamic and hormonal responses during captopril therapy for heart failure: acute, chronic and withdrawal studies. Am J Cardiol. 1982 Apr 21;49(6):1497–1501. doi: 10.1016/0002-9149(82)90367-8. [DOI] [PubMed] [Google Scholar]
  15. Sahn D. J., DeMaria A., Kisslo J., Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978 Dec;58(6):1072–1083. doi: 10.1161/01.cir.58.6.1072. [DOI] [PubMed] [Google Scholar]
  16. Tauxe W. N., Maher F. T., Taylor W. F. Effective renal plasma flow: estimation from theoretical volumes of distribution of intravenously injected 131-I orthoiodohippurate. Mayo Clin Proc. 1971 Aug;46(8):524–531. [PubMed] [Google Scholar]
  17. Williams E. D., Boddy K., Harvey I., Haywood J. K. Calibration and evaluation of a system of total body in vivo activation analysis using 14 MeV neutrons. Phys Med Biol. 1978 May;23(3):405–415. doi: 10.1088/0031-9155/23/3/004. [DOI] [PubMed] [Google Scholar]
  18. Zelis R., Flaim S. F., Moskowitz R. M., Nellis S. H. How much can we expect from vasodilator therapy in congestive heart failure? Circulation. 1979 Jun;59(6):1092–1097. doi: 10.1161/01.cir.59.6.1092. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES